EverHint – Dip Bounce V2 (Reclaim) – Top 10 Signals for Nov 03, 2026
Excerpt: 10 signals (from 17 total). Communication Services leads (6). price range $6-$230. 2 with insider selling.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
The mixed index performance on November 3rd, 2026 reveals a market in selective rotation rather than broad-based momentum. The Nasdaq's outperformance at +0.83% versus the Dow's slight decline of -0.38% signals that growth and technology-adjacent sectors are absorbing capital flows, while more defensive or cyclical names face headwinds. This divergence creates a constructive backdrop for dip-bounce reclaim strategies, as pockets of strength suggest buyers are active and willing to step in at key technical levels rather than broadly retreating.
The VIX sitting at 20.83, down 1.51% on the day, reflects a moderating but still elevated fear environment. This level of implied volatility is a double-edged dynamic for intraday swing signals — it provides enough price movement to generate meaningful bounce setups, while the declining trend in volatility suggests panic-selling is easing, which is precisely the condition where reclaim patterns tend to resolve cleanly to the upside. Traders should expect intraday ranges to remain wide enough to validate entries but not so erratic as to trigger excessive noise around stop levels.
The concentration of signals in Communication Services aligns logically with the Nasdaq's relative strength, as this sector carries significant growth-oriented weighting and tends to attract momentum capital during risk-on rotations. With 17 total signals skewed toward this sector, the dip-bounce reclaim framework is essentially betting on continued sector rotation into growth names — a thesis supported by the current index divergence. Risk appetite appears measured but present, favoring disciplined entries on confirmed reclaims rather than aggressive anticipatory positioning.
📊 Signals (10 of 17 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | BAX | Baxter International Inc. | Healthcare | $25.49 | 0.30 | — | $13.2B |
| 2 | BTSG | BrightSpring Health Se... | Healthcare | $69.84 | 0.18 | — | $13.8B |
| 3 | JAZZ | Jazz Pharmaceuticals plc | Healthcare | $229.74 | 0.16 | — | $14.9B |
| 4 | FWONK | Liberty Media Corporation | Communication Services | $95.56 | 0.16 | — | $24.0B |
| 5 | LILAK | Liberty Latin America ... | Communication Services | $8.67 | 0.15 | — | $2.6B |
| 6 | NWL | Newell Brands Inc. | Consumer Defensive | $5.63 | 0.14 | — | $2.4B |
| 7 | BATRA | Atlanta Braves Holding... | Communication Services | $56.41 | 0.14 | — | $3.6B |
| 8 | FWONA | Formula One Group | Communication Services | $87.84 | 0.14 | — | $22.0B |
| 9 | BATRK | Atlanta Braves Holding... | Communication Services | $51.73 | 0.14 | — | $3.3B |
| 10 | LILA | Liberty Latin America ... | Communication Services | $8.73 | 0.13 | — | $2.6B |
Recent Headlines
BATRA (Atlanta Braves Holdings, Inc.)
- StoneX reiterates Buy rating on Liberty Braves stock ahead of earnings
BAX (Baxter International Inc.)
- International Assets Investment Management LLC Acquires 72,405 Shares of Baxter International Inc. $BAX
BTSG (BrightSpring Health Services, Inc. Common Stock)
- Why BrightSpring Health Services, Inc. (BTSG) is a Top Value Stock for the Long-Term
- Guggenheim raises BrightSpring Health stock price target on growth
JAZZ (Jazz Pharmaceuticals plc)
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
- JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View
- 4 Biotech Stocks Seeing Unusual Options Volume Today
- Baird reiterates Jazz Pharmaceuticals stock rating on sleep franchise
- Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
NWL (Newell Brands Inc.)
- NWL vs. CHD: Which Stock Is the Better Value Option?
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.